Explore the Agenda
8:30 am Check-In Opens & Light Breakfast
8:50 am Chair’s Opening Remarks
Improving Solid Tumour Treatments by Leveraging Multi-Effector Cell Engagement & Affinity Tuning to Widen the Therapeutic Window
9:00 am Developing Novel Gamma Delta T Cell Engager Therapies; CYT X300 a Pan Gamma Delta T Cell Engager Targeting EGFR Positive Solid Tumours
- Cytospire is developing next generation T-cell engagers targeting γδ T-cells
- Our engagers are designed to enhance and direct key effector cells of the innate and adaptive immune system, providing a safer alternative to CD3 based engagers
- In the presentation I will describe preclinical data supporting development of CYT X300, a first-in-class pan-gamma delta T-cell engager targeting EGFR
9:30 am Session Details to Be Revealed
10:00 am Refining T Cell Bispecifics by Incorporating Competitive Binding & Affinity Tuning Strategies to Improve Solid Tumour Therapy
- Exploring novel approaches including competitive binding strategies and presaturation with blocking antibodies to improve tumour penetration and widen the therapeutic window
- Multi-effector engagement for enduring tumour control
- Leveraging affinity tuning to exploit differential antigen expression, using lower-affinity binders to selectively target tumours with higher antigen density
10:30 am Morning Break & Networking
Fine-Tuning TCE Engineering & Target Selection to Achieve Deeper & More Durable Treatments for Autoimmune Diseases
11:30 am CD1a-Targeted PD-1 Agonists for Localised Immunosuppression in Atopic Dermatitis
- IMC-U120AI is a novel, first in class skin targeted PD-1 agonist bispecific (ImmTAI) to provide localised immune inhibition for the treatment of Atopic Dermatitis
- CD1a-targeted PD-1 agonists show potent inhibition of CD4+T-cells and NK cells
- IMC-U120AI is the first Immunocore ‘universal’ therapy
12:00 pm Strategies for Selective Pathogenic B Cell Depletion in Inflammatory Diseases
- Identifying disease-specific B cell populations driving autoimmune diseases
- Benefit and challenges of targeting pathogenic B cells; identification of disease relevant animal models
- Prioritising targets by balancing specificity, patient coverage, and safety to enable precision depletion while minimising off-target immune suppression
12:30 pm Lunch & Networking
Uncovering Preclinical Data for Novel T-Cell Engager Engineering Approaches to Discover Strategies for Mitigating Toxicity & Optimising Potency
1:30 pm Unlocking Safe & Potent T-Cell Engagers by Applying Rational Design Principles to Maximise Efficacy & Minimise Toxicity
- Tuning affinity, valency and format to efficiently form immune synapse
- Engineering CD8 T-cell selectivity to minimise CRS and ICANS without compromising therapeutic potency
- Presenting pre-clinical data on leading programs entering clinical trial
2:00 pm Conditionally Active, Dual-Targeting BiTAC-TCEs for the Treatment of Solid Tumours
- Our BiTAC-TCE platform is designed to overcome the on-target, off-tumour toxicities of conventional (mono-targeting) TCEs
- AND-gated targeting of antigen pairs together with an on-cell assembly of a split anti-CD3 increases the selectivity to dual antigen-positive tumour cells
- In vitro and in vivo data of several programs including our most advanced preclinicalstage* EpCAM-targeting BiTAC-TCE will be presented
2:30 pm Afternoon Break & Networking
Accelerating Translation with Advanced Preclinical Modelling, Dosing & Clinical Strategies to Deliver Durable Therapeutics & Achieve Regulatory Approval
3:00 pm Effecting Immune Reset through Deep B-Cell Depletion with CLN-978: Early Clinical & Translational Insights
- Summarising emerging clinical data evaluating the safety, tolerability, and preliminary clinical activity of the CD19 x CD3 TCE CLN-978 across autoimmune patient populations
- Characterising the depth, durability, and tissue-level impact of B-cell depletion achieved through enhanced target engagement and extended half-life design
- Describing how emerging clinical and biomarker observations for CLN-978 can be utilised to rapidly advance the development of T cell engagers in autoimmune disease indications
3:30 pm Panel Discussion: Navigating Preclinical, Translational & Clinical Bottlenecks by Evaluating Key Learnings to Accelerate TCEs Towards Approval
- How to improve preclinical models to better predict activity, clinical safety and de-risk translation into the clinic?
- How are next-generation preclinical platforms (e.g. organoids, humanised models, ex vivo systems) enabling evaluation of conditional activation and masking strategies?
- How can translational biomarker strategies, including antigen density thresholds and T-cell fitness profiling, improve patient stratification and clinical signal prediction?
- What will regulators most want to see before they are comfortable with first-in-human studies in these settings?
4:00 pm Fine-Tuning T-cell-Targeting Therapies Through Affinity Engineering & Dosing Strategy
- Optimisation strategies for T-cell–targeting modalities: CD3 affinity modulation in T-cell engagers and dosing adaptation for T-cell co-stimulatory bispecific antibodies to improve benefit–risk, T-cell fitness and durability
- Comparative studies of two B7-H4 CD3 bispecific antibodies show that lower CD3 affinity reduces tumor cell killing and cytokine secretion while improving tolerability in cynomolgus monkeys
- Clinical acasunlimab + pembrolizumab data reveal less frequent dosing promotes T-cell rest and improves anti-tumor immune responses